Empress Therapeutics Appoints Virginia Finnerty-Brooks Chief Business Officer
Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Virginia Finnerty-Brooks has been appointed Chief Business Officer (CBO).
- Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Virginia Finnerty-Brooks has been appointed Chief Business Officer (CBO).
- With more than 25 years of corporate development and operational experience, Ms. Finnerty-Brooks will work closely with the Empress leadership team and board to drive corporate development, including industry partnerships, academic research collaborations, and operational excellence.
- “Virginia has repeatedly created and delivered value-generating business opportunities at companies big and small in multiple categories over the course of her career,” said Jason Park, Ph.D., Co-Founder and CEO of Empress.
- She holds a master’s in business administration from Saint Joseph’s University and a bachelor’s degree from Temple University.